Chemical Science

EDGE ARTICLE

View Article Online
View Journal | View Issue



Cite this: *Chem. Sci.*, 2016, **7**, 2827

# Systematic chemoenzymatic synthesis of *O*-sulfated sialyl Lewis *x* antigens†

Abhishek Santra,[a] Hai Yu,[a] Nova Tasnima,[a] Musleh M. Muthana,‡[a] Yanhong Li,[a] Jie Zeng,[ab] Nicholas J. Kenyon,[c] Angelique Y. Louie[d] and Xi Chen*[a]

Received 29th October 2015
Accepted 14th December 2015

DOI: 10.1039/c5sc04104j

www.rsc.org/chemicalscience

*O*-Sulfated sialyl Lewis *x* antigens play important roles in nature. However, due to their structural complexity, they are not readily accessible by either chemical or enzymatic synthetic processes. Taking advantage of a bacterial sialyltransferase mutant that can catalyze the transfer of different sialic acid forms from the corresponding sugar nucleotide donors to Lewis *x* antigens, which are fucosylated glycans, as well as an efficient one-pot multienzyme (OPME) sialylation system, *O*-sulfated sialyl Lewis *x* antigens containing different sialic acid forms and *O*-sulfation at different locations were systematically synthesized by chemoenzymatic methods.

## Introduction

*O*-Sulfated sialyl Lewis *x* structures play important roles in immune regulation, inflammation, and cancer metastasis.[1] For example, 6-*O*-sulfo-sialyl Lewis *x* [6-*O*-sulfo-sLe$^x$ (**1**), Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAc6SβOR] with an *O*-sulfate group at the carbon-6 of the *N*-acetylglucosamine (GlcNAc) residue (Fig. 1) is a well known ligand for L-selectin, a C-type ($Ca^{2+}$-dependent) carbohydrate-binding protein (lectin) expressed broadly in most leukocytes in the blood.[1,2] The interaction of 6-*O*-sulfo-sLe$^x$ (**1**) and L-selectin plays a critical role in lymphocyte homing to the peripheral lymph nodes[2] and in chronic inflammation.[3] It has also been shown that human sialic acid-binding immunoglobulin-like lectin[4] Siglec-9 binds strongly[5,6] to 6-*O*-sulfo-sLe$^x$, but the biological importance of this interaction is less well understood.

On the other hand, 6′-*O*-sulfo-sialyl Lewis *x* [6′-*O*-sulfo-sLe$^x$ (**2**), Neu5Acα2-3Gal6Sβ1-4(Fucα1-3)GlcNAcβOR] with an *O*-sulfate group at the carbon-6 of the galactose (Gal) residue (Fig. 1),[7] in addition to 6′-*O*-sulfo-sialyl-*N*-acetyllactosamine (6′-*O*-sulfo-sLacNAc, Neu5Acα2-3Gal6Sβ1-4GlcNAcβOR),[8] was shown by glycan microarray studies to be a preferred glycan ligand for Siglec-8 and for its paralog mouse Siglec-F.[9] Siglec-8 is expressed in human allergic inflammatory cells including eosinophils, mast cells, and basophils.[5,10] Reducing the number of eosinophils, such as by soluble 6′-*O*-sulfo-sLe$^x$ synthetic polymer induced apoptosis,[11] has been suggested as an approach for asthma therapies.[12] Furthermore, 6′-*O*-sulfo-sLe$^x$ (**2**), in addition to 6′-*O*-sulfo-sLacNAc and 6′-*O*-sulfo-sialyl-lacto-*N*-neotetraose (6′-*O*-sulfo-sLNnT, Neu5Acα2-3Gal6Sβ1-4GlcNAcβ1-3Galβ1-4GlcβOR), was shown to bind to langerin,[13] a C-type ($Ca^{2+}$-dependent) lectin specific to Langerhans cells (immature antigen-presenting specific T cell immunity initiating dendritic cells of epidermis and mucosal tissues).[14]

Although less efficient than Neu5Acα2-8Neu5Acα2-3LacNAc, both 6-*O*-sulfo-sLe$^x$ (**1**) and 6′-*O*-sulfo-sLe$^x$ (**2**) bound moderately




Fig. 1 Structures of *O*-sulfated sialyl Lewis *x* including 6-*O*-sulfo-sLe$^x$ (**1**), 6′-*O*-sulfo-sLe$^x$ (**2**), and 6′, 6-di-*O*-sulfo-sLe$^x$ (**3**).

[a]*Department of Chemistry, University of California, Davis One Shields Avenue, Davis, CA 95616, USA. E-mail: xiichen@ucdavis.edu; Fax: +1-530-752-8995; Tel: +1-530-754-6037*

[b]*School of Food Science, Henan Institute of Science and Technology, Xinxiang, 453003, China*

[c]*Division of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, University of California, Davis, CA 95616, USA*

[d]*Department of Biomedical Engineering, University of California, Davis, CA 95616, USA*

† Electronic supplementary information (ESI) available: Materials, experimental details of the synthesis, analytical data of **4–10**, **1a–3a**, and **1b–3b**, and NMR spectra of synthesized compounds. See DOI: 10.1039/c5sc04104j

‡ Current address: Children's National Medical Center, Washington DC, 20010, USA.

to human Siglec-7.[5] Both are present in glycosylation-dependent cell adhesion molecule 1 (GlyCAM-1), an L-selectin ligand,[15] with 6′-*O*-sulfo-sLe$^x$ (**2**) as the major sulfated form.[16–18] Gal-6-*O*-sulfotransferase and GlcNAc-6-*O*-sulfotransferase have been found to synergistically produce L-selectin ligands. This indicates either the potential synergistic involvement of both 6-*O*-sulfo-sLe$^x$ (**1**) and 6′-*O*-sulfo-sLe$^x$ (**2**) or the involvement of 6′,6-di-*O*-sulfo-sLe$^x$ (**3**) (Fig. 1) with *O*-sulfate groups at both the Gal and GlcNAc residues of sLe$^x$ in L-selectin-binding.[19] Human Siglec-7 and -8 have also been shown to bind more strongly to 6′,6-di-*O*-sulfo-sLe$^x$ (**3**) than their mono-*O*-sulfated derivatives (**1** and **2**), while mouse Siglec-F has been shown to bind with similar strength to 6′,6-di-*O*-sulfo-sLe$^x$ (**3**) and 6′-*O*-sulfo-sLe$^x$ (**2**).[6]

The biological importance of *O*-sulfated sLe$^x$ structures makes them attractive synthetic targets. However, the structures of these compounds are relatively complex and include synthetically challenging α2-3-linked sialic acid, which suffers from low stereoselectivity and a high 2,3-elimination rate in chemical synthesis,[20–22] as well as the acid labile *O*-sulfate group.[23,24] Chemically[20,25,26] or chemoenzymatically[27] synthesized Neu5Acα2-3Gal building blocks have been used as effective synthons for constructing more complex sialosides including sLe$^x$ and 6-*O*-sulfo-sLe$^x$ (**1**).[20] Several examples of the chemical[22,28] or chemoenzymatic[29] synthesis of 6-*O*-sulfo-sLe$^x$ (**1**) as well as the chemical synthesis of 6′-*O*-sulfo-sLe$^x$ (**2**)[22,30,31] and 6′,6-di-*O*-sulfo-sLe$^x$ (**3**)[32] have been reported. All these examples are, however, limited to compounds with the most abundant sialic acid form, *N*-acetylneuraminic acid (Neu5Ac). Despite the presence of more than 50 different sialic acid forms identified in nature,[33,34] *O*-sulfated sLe$^x$ containing a sialic acid form other than Neu5Ac has not been synthesized.

We report here the development of efficient chemoenzymatic methods for the systematic synthesis of *O*-sulfated sLe$^x$ containing different sialic acid forms. The methods are demonstrated for representative examples of 6′-*O*-sulfo-sLe$^x$ (**1**), 6-*O*-sulfo-sLe$^x$ (**2**) and/or 6′,6-di-*O*-sulfo-sLe$^x$ (**3**) containing the most abundant Neu5Ac form and *N*-glycolylneuraminic acid (Neu5Gc), a sialic acid form commonly found in mammals other than humans, but which can be incorporated into the human glycome from dietary sources.[35]

One efficient approach for the synthesis of *O*-sulfated sLe$^x$ with different sialic acid forms would be by direct sialylation of *O*-sulfated Le$^x$ using one-pot multienzyme (OPME) sialylation systems[36] containing an α2-3-sialyltransferase and a CMP-sialic acid synthetase (CSS),[37] with or without a sialic acid aldolase.[38] Such an approach has been successfully demonstrated for direct sialylation of non-sulfated Le$^x$ for the synthesis of sLe$^x$ containing a diverse array of naturally occurring and non-natural sialic acid forms, using OPME systems containing a recombinant viral α2-3-sialyltransferase vST3Gal-I[39] or a bacterial multifunctional sialyltransferase mutant, *Pasteurella*




Fig. 2 Structures of chemically synthesized 6′-*O*-sulfo-LacNAcβProN$_3$ (**5**) and 6,6′-di-*O*-sulfo-LacNAcβProN$_3$ (**6**).




Scheme 1 Sequential OPME synthesis of 6-*O*-sulfo-Le$^x$βProN$_3$ (**8**) from 6-*O*-sulfo-GlcNAcβProN$_3$ (**7**) using an OPME β1-4-galactosyl activation and transfer system for the formation of 6-*O*-sulfo-LacNAcβProN$_3$ (**4**) followed by an OPME α1-3-fucosyl activation and transfer system for the formation of 6-*O*-sulfo-Le$^x$βProN$_3$ (**8**). Enzymes and abbreviations: SpGalK, *Streptococcus pneumoniae* TIGR4 galactokinase;[44] BLUSP, *Bifidobacterium longum* UDP-sugar pyrophosphorylase;[45] PmPpA, *Pasteurella multocida* inorganic pyrophosphorylase;[43] Hp4GalT, *Helicobacter pylori* β1-4-galactosyltransferase;[43] BfFKP, *Bacteroides fragilis* bifunctional L-fucokinase/GDP-fucose pyrophosphorylase;[42] and Hp3FT, *Helicobacter pylori* α1-3-fucosyltransferase.[39,41]




Scheme 2 Chemical synthesis of 6′-*O*-sulfo-Le$^x$βProNH$_2$ (**9**) and 6,6′-di-*O*-sulfo-Le$^x$βProNH$_2$ (**10**). Reagents and conditions: (a) *N*-iodosuccinimide (NIS), TMSOTf, MS 4 Å, $CH_2Cl_2$, −40 °C, 30 min; (b) *N*-iodosuccinimide (NIS), TMSOTf, MS 4 Å, $CH_2Cl_2$–$Et_2O$ (1 : 1), −18 °C, 45 min; (c) $H_2N(CH_2)_2NH_2$, *n*-BuOH, 90 °C, 8 h; (d) pyridine, $Ac_2O$, r.t., 10 h; (e) HF pyridine, 0 °C to r.t., overnight; (f) $SO_3$ pyridine, pyridine, 0 °C to r.t.; (g) 0.1 M NaOMe, MeOH, r.t., 3 h; (h) Pd(OH)$_2$/C, $H_2$, $CH_3OH$, 48 h.




Scheme 3 PmST1 M144D-mediated one-pot two-enzyme (OP2E) sialylation of *O*-sulfo analogues of Lewis$^x$. Yields obtained for *O*-sulfated sLe$^x$ tetrasaccharides: **1a**, 85%; **1b**, 47%; **2a**, 82%; **2b**, 60%; **3a**, 64%; **3b**, 38%. Enzymes and abbreviations: NmCSS, *Neisseria meningitidis* CMP-sialic acid;[37] PmST1 M144D, *Pasteurella multocida* α2-3-sialyltransferase 1 (PmST1) M144D mutant.[40]

*multocida* α2-3-sialyltransferase 1 (PmST1) M144D.[40] The latter, with a high expression level (98 mg $L^{-1}$ culture, >1000-fold higher than that of vST3Gal-I) and high promiscuity in tolerating different modifications on the sialic acid in the substrates, is a superior choice for the synthesis.[40] However, it is not clear whether *O*-sulfated Le$^x$ structures could be used with PmST1 M144D as suitable acceptors in the OPME sialylation process to produce the desired *O*-sulfated sLe$^x$ with different sialic acid forms.

## Results and discussion

### Synthesis of *O*-sulfated disaccharides and *O*-sulfated Le$^x$

In order to obtain *O*-sulfated Le$^x$ as potential acceptor substrates for PmST1 M144D, enzyme-catalyzed α1-3-fucosylation of the corresponding *O*-sulfated disaccharides was tested as a potential strategy. A one-pot three-enzyme (OP3E) α1-3-fucosylation system (Scheme 1)[39,41] containing *Bacteroides fragilis* bifunctional L-fucokinase/GDP-fucose pyrophosphorylase (BfFKP),[42] *Pasteurella multocida* inorganic pyrophosphorylase (PmPpA),[43] and *Helicobacter pylori* α1-3-fucosyltransferase (Hp1-3FTΔ66 or Hp3FT) was used for this purpose. The *O*-sulfated disaccharides tested were 6-*O*-sulfo-LacNAcβProN$_3$ (**4**) (Scheme 1), 6′-*O*-sulfo-LacNAcβProN$_3$ (**5**), and 6,6′-di-*O*-sulfo-LacNAcβProN$_3$ (**6**) (Fig. 2). LacNAcβProN$_3$ (ref. 43) without any *O*-sulfate groups was used as a positive control.

6-*O*-Sulfo-LacNAcβProN$_3$ (**4**) was synthesized from 6-*O*-sulfo-GlcNAcβProN$_3$ (**7**)[43] using an improved OPME galactosyl activation and transfer system (Scheme 1) containing *Streptococcus pneumoniae* TIGR4 galactokinase (SpGalK),[44] *Bifidobacterium longum* UDP-sugar pyrophosphorylase (BLUSP),[45] PmPpA, and a *Helicobacter pylori* β1-4-galactosyltransferase (Hp1-4GalT or Hp4GalT).[43] The EcGalK, BLUSP, and PmPpA allowed *in situ* formation of the donor substrate of Hp4GalT, uridine 5′-diphosphate-galactose (UDP-Gal), from monosaccharide galactose (Gal).[45] It was previously shown that Hp4GalT, but not *Neisseria meningitidis* β1-4-galactosyltransferase (NmLgtB), was able to use 6-*O*-sulfated GlcNAc and derivatives as acceptor substrates for the synthesis of β1-4-linked galactosides.[43] The activity of Hp4GalT in synthesizing 6-*O*-sulfo-LacNAcβProN$_3$ (**4**) was confirmed again here using the improved OPME approach.[45,46] An excellent 89% yield was obtained, comparing favourably to the previous Hp4GalT-dependent OPME β1-4-galactosylation approach (70% yield) which used *Escherichia coli* K-12 glucose-1-P uridylyltransferase (EcGalU), *Escherichia coli* UDP-galactose-4-epimerase (EcGalE), and PmPpA to produce UDP-Gal *in situ* from glucose-1-phosphate.[43] 6′-*O*-Sulfo-LacNAcβProN$_3$ (**5**) and 6,6′-di-*O*-sulfo-LacNAcβProN$_3$ (**6**) (Fig. 2) were chemically synthesized (see ESI†).

Among the three *O*-sulfated disaccharides tested, only 6-*O*-sulfo-LacNAcβProN$_3$ (**4**) was a suitable acceptor for Hp3FT to produce the desired 6-*O*-sulfo-Le$^x$βProN$_3$ (**8**). In contrast, 6′-*O*-sulfo-LacNAcβProN$_3$ (**5**) and 6,6′-di-*O*-sulfo-LacNAcβProN$_3$ (**6**) were not used efficiently by Hp3FT for the synthesis of the corresponding *O*-sulfated Le$^x$ derivatives. With the positive outcome in small scale reactions for fucosylation of 6-*O*-sulfo-LacNAcβProN$_3$ (**4**), the preparative-scale synthesis of 6-*O*-sulfo-Le$^x$βProN$_3$ (**8**) was carried out using the OP3E α1-3-fucosyl activation and transfer system (Scheme 1). A yield of 70% was obtained. The combined sequential OPME β1-4-galactosylation and OPME α1-3-fucosylation (Scheme 1) was an effective approach for obtaining 6-*O*-sulfo-Le$^x$βProN$_3$ (**8**) from a simple monosaccharide derivative 6-*O*-sulfo-GlcNAcβProN$_3$ (**7**) in an overall yield of 62%.

As Hp3FT was not able to use 6′-*O*-sulfo-LacNAcβProN$_3$ (**5**) or 6,6′-di-*O*-sulfo-LacNAcβProN$_3$ (**6**) efficiently as acceptors for fucosylation to obtain the desired Le$^x$ trisaccharides, the target trisaccharides 6′-*O*-sulfo-Le$^x$βProNH$_2$ (**9**) and 6,6′-di-*O*-sulfo-Le$^x$βProNH$_2$ (**10**) were chemically synthesized (Scheme 2) from monosaccharide synthons **11**, **12**,[27] **13**, and **14**.[27] Notable features of the synthetic strategy include: (a) application of an efficient general protection strategy[47] for the synthesis of the two trisaccharides (*i.e.* similar protecting groups were used in the syntheses and the same reagents were used for their removal); (b) use of similar thioglycoside derivatives as glycosyl donors in all glycosylations; (c) high regio- and stereoselectivity in product formation; (d) one step removal of benzyl ethers and reduction of the azido group using 20% Pd(OH)$_2$/C (Pearlman's catalyst) and H$_2$.[48] More specifically, for the synthesis of **9** and **10**, two *N*-phthalimide glucosamine derivatives **11** and **12** selectively protected at C6 with benzyl and *tert*-butyldiphenylsilyl ether (TBDPS), respectively, were coupled stereoselectively with thioglycoside donor **13**, which was selectively protected with TBDPS at C6, in the presence of *N*-iodosuccinimide (NIS) and trimethylsilyl trifluoromethanesulfonate (TMSOTf)[49] in dichloromethane. Disaccharide derivatives **15** and **16** were obtained in 72% and 78% yields, respectively. The bulky *N*-phthalimido protecting group in acceptors **11** and **12** provides steric hindrance to the neighboring C-3 hydroxyl group and decreases the reactivity of the C-3 hydroxyl group. Therefore, glycosylation occurs regioselectively at the C-4 hydroxyl group.[27] Initial attempts to glycosylate acceptors **15** and **16** in

dichloromethane with 1.2 equivalents of thiophenyl fucoside **14** produced trisaccharides in alpha and beta mixtures. In contrast, stereospecific formation of trisaccharides was achieved when a mixed solvent of diethylether and dichloromethane (1 : 1)[50,51] was employed. The reaction of acceptors **15** and **16** with 1.2 equivalents of fucosyl donor **14** produced compounds **17** and **18** in 68% and 65% yields, respectively. Compounds **17** and **18** were then subjected to a series of synthetic transformations: (a) conversion of the *N*-phthaloyl group to an acetamido group by removing the phthaloyl group using ethylenediamine, followed by *N*- and *O*-acetylation using acetic anhydride and pyridine; (b) HF-pyridine-mediated selective removal of the TBDPS group;[52] (c) *O*-sulfation of the primary hydroxyl group by $SO_3$ pyridine complex;[52,53] (d) deacetylation by NaOMe in MeOH;[54] and (e) hydrogenation using $Pd(OH)_2$/C and $H_2$ (ref. 55) to obtain the desired 6′-*O*-sulfo-Le$^x$βProNH$_2$ (**9**) and 6,6′-di-*O*-sulfo-Le$^x$βProNH$_2$ (**10**).

### Enzymatic synthesis of *O*-sulfated sLe$^x$

With chemoenzymatically synthesized 6-*O*-sulfo-Le$^x$βProN$_3$ (**8**) as well as chemically synthesized 6′-*O*-sulfo-Le$^x$βProNH$_2$ (**9**) and 6,6′-di-*O*-sulfo-Le$^x$βProNH$_2$ (**10**) in hand, a one-pot two-enzyme (OP2E) sialylation system (Scheme 3) was used to test the tolerance of PmST1 M144D[40] for using these *O*-sulfated Le$^x$ compounds as potential acceptor substrates. PmST1 M144D was previously engineered by protein crystal structure-assisted design. It has 20-fold reduced CMP-sialic acid (donor) hydrolysis activity and significantly (5588-fold) decreased α2-3-sialidase activity compared to the wild-type enzyme. It was used efficiently in a one-pot three-enzyme (OP3E) sialylation system for the synthesis of non-sulfated sLe$^x$ tetrasaccharides containing diverse sialic acid forms from Le$^x$.[40] To our delight, PmST1 M144D also tolerated *O*-sulfated Le$^x$ containing *O*-sulfate at C-6, C-6′, or both. In addition to *N*-acetylneuraminic acid (Neu5Ac), *N*-acetylneuraminic acid (Neu5Gc) was also successfully introduced to compounds **8–10**. *O*-Sulfated sLe$^x$ tetrasaccharides 6-*O*-sulfo-Neu5Acα2-3Le$^x$βProN$_3$ (**1a**, 80 mg, 85%), 6-*O*-sulfo-Neu5Gcα2-3Le$^x$βProN$_3$ (**1b**, 22 mg, 47%), 6′-*O*-sulfo-Neu5Acα2-3Le$^x$βProNH$_2$ (**2a**, 75 mg, 82%), 6′-*O*-sulfo-Neu5Acα2-3Le$^x$βProNH$_2$ (**2b**, 45 mg, 60%), 6,6′-di-*O*-sulfo-Neu5Acα2-3Le$^x$βProNH$_2$ (**3a**, 42 mg, 64%), and 6,6′-di-*O*-sulfo-Neu5Gcα2-3Le$^x$βProNH$_2$ (**3b**, 40 mg, 38%) were successfully obtained using this highly efficient one-pot two-enzyme system containing *Neisseria meningitidis* CMP-sialic acid (NmCSS)[37] and PmST1 M144D[40] from the corresponding acceptors **8–10** and Neu5Ac or Neu5Gc, respectively. In general, Neu5Gc was used less efficiently by the OPME sialylation system, leading to lower yields for **1b–3b** (38–60%) compared to their Neu5Ac-counterparts **1a–3a** (64–85%). *O*-Sulfated sLe$^x$ glycans with a propyl amine aglycone (compounds **2a**, **3a**, **2b** and **3b**) were found to be more challenging for column purification compared to the ones with a propyl azide aglycone (compounds **1a** and **1b**). When a desired sialic acid is readily available such as in the case presented here, a one-pot two-enzyme (OP2E) system is sufficient. When only the 6-carbon precursors of the desired sialic acid forms are available, the one-pot three-enzyme (OP3E) sialylation system including an aldolase in addition to NmCSS and PmST1 M144D[40] should be used.

## Conclusions

In conclusion, we have successfully developed an efficient chemoenzymatic method for the systematic synthesis of synthetically challenging *O*-sulfated sLe$^x$ (**1a–3a** and **1b–3b**) containing different sialic acid forms (Neu5Ac or Neu5Gc) by direct sialylation of the corresponding *O*-sulfated Le$^x$ structures **8–10** using an efficient one-pot two-enzyme (OP2E) system containing NmCSS and PmST1 M144D. The method can be extended to the synthesis of *O*-sulfated sLe$^x$ structures containing other sialic acid forms. We have also shown here that a relatively complex trisaccharide 6-*O*-sulfo-Le$^x$βProN$_3$ (**8**) can be efficiently produced from a simple monosaccharide derivative 6-*O*-sulfo-GlcNAcβProN$_3$ (**7**) by a sequential OPME β1-4-galactosylation and OPME α1-3-fucosylation process. PmST1 M144D has been demonstrated to be a powerful catalyst not only for synthesizing non-sulfated sLe$^x$ structures as shown previously,[40] but also for producing biologically important but difficult-to-obtain *O*-sulfated sLe$^x$.

## Acknowledgements

This work was supported by NIH grants R01GM094523 (to X. C.) and R21AI097354 (to A. Y. L.) as well as NSF grant CHE-1300449 (to X. C.). M. M. M. acknowledges UC-Davis and USDE for a GAANN Fellowship (P200A120187). A Bruker Avance-800 NMR spectrometer was funded by NSF grant DBIO-722538.

## References

1 S. D. Rosen, *Annu. Rev. Immunol.*, 2004, **22**, 129.
2 H. Kawashima and M. Fukuda, *Ann. N. Y. Acad. Sci.*, 2012, **1253**, 112.
3 M. Kobayashi, H. Lee, J. Nakayama and M. Fukuda, *Curr. Drug Metab.*, 2009, **10**, 29.
4 M. S. Macauley, P. R. Crocker and J. C. Paulson, *Nat. Rev. Immunol.*, 2014, **14**, 653.
5 T. Kiwamoto, N. Kawasaki, J. C. Paulson and B. S. Bochner, *Pharmacol. Ther.*, 2012, **135**, 327.
6 M. A. Campanero-Rhodes, R. A. Childs, M. Kiso, S. Komba, C. le Narvor, J. Warren, D. Otto, P. R. Crocker and T. Feizi, *Biochem. Biophys. Res. Commun.*, 2006, **344**, 1141.
7 B. S. Bochner, R. A. Alvarez, P. Mehta, N. V. Bovin, O. Blixt, J. R. White and R. L. Schnaar, *J. Biol. Chem.*, 2005, **280**, 4307.
8 T. Kiwamoto, M. E. Brummet, F. Wu, M. G. Motari, D. F. Smith, R. L. Schnaar, Z. Zhu and B. S. Bochner, *J. Allergy Clin. Immunol.*, 2014, **133**, 240.
9 H. Tateno, P. R. Crocker and J. C. Paulson, *Glycobiology*, 2005, **15**, 1125.
10 B. S. Bochner, *Clin. Exp. Allergy*, 2009, **39**, 317.
11 S. A. Hudson, N. V. Bovin, R. L. Schnaar, P. R. Crocker and B. S. Bochner, *J. Pharmacol. Exp. Ther.*, 2009, **330**, 608.

 

12 T. Kiwamoto, T. Katoh, C. M. Evans, W. J. Janssen, M. E. Brummet, S. A. Hudson, Z. Zhu, M. Tiemeyer and B. S. Bochner, *J. Allergy Clin. Immunol.*, 2015, **135**, 1329.
13 C. Galustian, C. G. Park, W. Chai, M. Kiso, S. A. Bruening, Y. S. Kang, R. M. Steinman and T. Feizi, *Int. Immunol.*, 2004, **16**, 853.
14 J. Valladeau, O. Ravel, C. Dezutter-Dambuyant, K. Moore, M. Kleijmeer, Y. Liu, V. Duvert-Frances, C. Vincent, D. Schmitt, J. Davoust, C. Caux, S. Lebecque and S. Saeland, *Immunity*, 2000, **12**, 71.
15 L. A. Lasky, M. S. Singer, D. Dowbenko, Y. Imai, W. J. Henzel, C. Grimley, C. Fennie, N. Gillett, S. R. Watson and S. D. Rosen, *Cell*, 1992, **69**, 927.
16 S. Hemmerich and S. D. Rosen, *Biochemistry*, 1994, **33**, 4830.
17 S. Hemmerich, H. Leffler and S. D. Rosen, *J. Biol. Chem.*, 1995, **270**, 12035.
18 S. Hemmerich, C. R. Bertozzi, H. Leffler and S. D. Rosen, *Biochemistry*, 1994, **33**, 4820.
19 A. Bistrup, S. Bhakta, J. K. Lee, Y. Y. Belov, M. D. Gunn, F. R. Zuo, C. C. Huang, R. Kannagi, S. D. Rosen and S. Hemmerich, *J. Cell Biol.*, 1999, **145**, 899.
20 G. V. Pazynina, M. A. Sablina, A. B. Tuzikov, A. A. Chinarev and N. V. Bovin, *Mendeleev Commun.*, 2003, **13**, 245.
21 C. H. Lai, H. S. Hahm, C. F. Liang and P. H. Seeberger, *Beilstein J. Org. Chem.*, 2015, **11**, 617.
22 A. K. Misra, Y. Ding, J. B. Lowe and O. Hindsgaul, *Bioorg. Med. Chem. Lett.*, 2000, **10**, 1505.
23 A. Liang, J. N. Thakkar and U. R. Desai, *J. Pharm. Sci.*, 2010, **99**, 1207.
24 R. A. Al-Horani and U. R. Desai, *Tetrahedron*, 2010, **66**, 2907.
25 L. Krock, D. Esposito, B. Castagner, C.-C. Wang, P. Bindschadler and P. H. Seeberger, *Chem. Sci.*, 2012, **3**, 1617.
26 D. Esposito, M. Hurevich, B. Castagner, C. C. Wang and P. H. Seeberger, *Beilstein J. Org. Chem.*, 2012, **8**, 1601.
27 H. Cao, S. Huang, J. Cheng, Y. Li, S. Muthana, B. Son and X. Chen, *Carbohydr. Res.*, 2008, **343**, 2863.
28 S. Komba, C. Galustian, H. Ishida, T. Feizi, R. Kannagi and M. Kiso, *Angew. Chem., Int. Ed.*, 1999, **38**, 1131.
29 M. R. Pratt and C. R. Bertozzi, *Org. Lett.*, 2004, **6**, 2345.
30 S. Komba, H. Ishida, M. Kiso and A. Hasegawa, *Bioorg. Med. Chem.*, 1996, **4**, 1833.
31 R. K. Jain, R. Vig, R. Rampal, E. V. Chandrasekaran and K. L. Matta, *J. Am. Chem. Soc.*, 1994, **116**, 12123.
32 S. Komba, H. Ishida, M. Kiso and A. Hasegawa, *Carbohydr. Res.*, 1996, **285**, C1.
33 X. Chen and A. Varki, *ACS Chem. Biol.*, 2010, **5**, 163.
34 T. Angata and A. Varki, *Chem. Rev.*, 2002, **102**, 439.
35 A. Varki, *Am. J. Phys. Anthropol.*, 2001, **116**(S33), 54.
36 H. Yu, H. A. Chokhawala, S. Huang and X. Chen, *Nat. Protoc.*, 2006, **1**, 2485.
37 H. Yu, H. Yu, R. Karpel and X. Chen, *Bioorg. Med. Chem.*, 2004, **12**, 6427.
38 Y. Li, H. Yu, H. Cao, K. Lau, S. Muthana, V. K. Tiwari, B. Son and X. Chen, *Appl. Microbiol. Biotechnol.*, 2008, **79**, 963.
39 G. Sugiarto, K. Lau, H. Yu, S. Vuong, V. Thon, Y. Li, S. Huang and X. Chen, *Glycobiology*, 2011, **21**, 387.
40 G. Sugiarto, K. Lau, J. Qu, Y. Li, S. Lim, S. Mu, J. B. Ames, A. J. Fisher and X. Chen, *ACS Chem. Biol.*, 2012, **7**, 1232.
41 H. Yu, K. Lau, Y. Li, G. Sugiarto and X. Chen, *Current Protocols in Chemical Biology*, 2012, **4**, 233.
42 W. Yi, X. Liu, Y. Li, J. Li, C. Xia, G. Zhou, W. Zhang, W. Zhao, X. Chen and P. G. Wang, *Proc. Natl. Acad. Sci. U. S. A.*, 2009, **106**, 4207.
43 K. Lau, V. Thon, H. Yu, L. Ding, Y. Chen, M. M. Muthana, D. Wong, R. Huang and X. Chen, *Chem. Commun.*, 2010, **46**, 6066.
44 M. Chen, L. L. Chen, Y. Zou, M. Xue, M. Liang, L. Jin, W. Y. Guan, J. Shen, W. Wang, L. Wang, J. Liu and P. G. Wang, *Carbohydr. Res.*, 2011, **346**, 2421.
45 X. Chen, J. W. Fang, J. B. Zhang, Z. Y. Liu, J. Shao, P. Kowal, P. Andreana and P. G. Wang, *J. Am. Chem. Soc.*, 2001, **123**, 2081.
46 H. Yu, K. Lau, V. Thon, C. A. Autran, E. Jantscher-Krenn, M. Xue, Y. Li, G. Sugiarto, J. Qu, S. Mu, L. Ding, L. Bode and X. Chen, *Angew. Chem., Int. Ed.*, 2014, **53**, 6687.
47 L. P. Miranda and M. Meldal, *Angew. Chem.*, 2001, **113**, 3767.
48 E. J. Corey and J. O. Link, *J. Am. Chem. Soc.*, 1992, **114**, 1906.
49 G. H. Veeneman, S. H. van Leeuwen and J. H. van Boom, *Tetrahedron Lett.*, 1990, **31**, 1331.
50 T. Ghosh, A. Santra and A. K. Misra, *RSC Adv.*, 2014, **4**, 54.
51 A. Si and A. K. Misra, *ChemistryOpen*, 2015, DOI: 10.1002/open.201500129.
52 B. Yang, K. Yoshida, Z. Yin, H. Dai, H. Kavunja, M. H. El-Dakdouki, S. Sungsuwan, S. B. Dulaney and X. Huang, *Angew. Chem., Int. Ed.*, 2012, **51**, 10185.
53 A. Santra, G. Guchhait and A. K. Misra, *Green Chem.*, 2011, **13**, 1345.
54 Z. Wang, in *Comprehensive Organic Name Reactions and Reagents*, John Wiley & Sons, Inc., 2010.
55 W. M. Pearlman, *Tetrahedron Lett.*, 1967, **8**, 1663.